Novartis Investigative Site

Kehl-Kork 77694

0 studies enrolling now · 4 studies all time

What they study most

Adrenocortical Adenoma, Endometrial Stromal Sarcomas, Partial Onset Seizures, Tuberous Sclerosis Complex-associated Refractory Seizures

Studies at this site

• Phase II BGG492 Capsule Extension for Partial Epilepsy — Completed
• Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures — Completed
• A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures — Completed
• Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 — Completed